Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer are impacting standard of care at Annual Meeting 2018.
The PROSPER and SPARTAN studies are impacting standard of care
